Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin and Pimavanserin in Major Depressive Disorder
NCT06592833Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimavanserin in major depressive disorder (MDD), sponsored by Icahn School of Medicine at Mount Sinai. Started Feb 2025; status: recruiting.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06592833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592833.